SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vasomedical Inc.
VASO 0.155-3.1%Dec 2 12:50 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Fred Levine who wrote (993)12/28/1998 10:03:00 PM
From: Michael Yang  Read Replies (1) of 1605
 
As published by a German research team, EECP treatment correlates with elevated blood level of VEGF (= involved in angiogenesis). This might explain the observation that EECP can generate lateral blood flows.

Could you elaborate on the "inevitable" reimbursement? Where did you hear about this?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News